Enterprise Value

4.224B

Cash

532.2M

Avg Qtr Burn

-22.2M

Short % of Float

12.08%

Insider Ownership

13.14%

Institutional Own.

89.72%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
VYJUVEKTM (B-VEC) (Topical Beremagene Geperpavec) Details
Skin disease/disorder, Dystrophic epidermolysis bullosa, Epidermolysis bullosa

Approved

Quarterly sales

KB105 Details
Autosomal recessive congenital ichthyosis , Skin disease/disorder

Phase 1/2

Initiation

KB407 Details
Cystic fibrosis

Phase 1

Data readout

Phase 1

Data readout

KB707 (IL-2 and IL-12) Details
Multiple tumors, Solid tumor/s

Phase 1

Initiation

KB408 Details
Severe alpha-1 antitrypsin deficiency

Phase 1

Initiation